1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Cogent Biosciences Acquires Kiq

M&A Deal Summary

Cogent Biosciences Acquires Kiq

On July 6, 2020, Cogent Biosciences acquired life science company Kiq

Acquisition Highlights
  • This is Cogent Biosciences’ 1st transaction in the Life Science sector.
  • This is Cogent Biosciences’ 1st transaction in the United States.

M&A Deal Summary
Date 2020-07-06
Target Kiq
Sector Life Science
Buyer(s) Cogent Biosciences
Deal Type Add-on Acquisition
Advisor(s) Wedbush Securities (Financial)
Gibson, Dunn & Crutcher (Legal)

Target

Kiq

United States
Kiq LLC is a biotechnology company focused on the discovery and development of precision kinase inhibitors.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Cogent Biosciences

Waltham, Massachusetts, United States
Category Company
Founded 2014
Sector Life Science
Employees205
Revenue 7M USD (2020)
DESCRIPTION

Cogent Biosciences is a biopharmaceutical company focused on developing a pipeline of novel therapies to treat cancer patients. Unum's most advanced program, PLX9486, is a highly potent and selective KIT D816V inhibitor that is being developed to treat systemic mastocytosis and GIST patients. Cogent Biosciences was founded in 2014 and is based in Waltham, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2020 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal